

Interim Term Financial Results Ended September 2021

November 9 , 2021
KYORIN Holdings, Inc.
President Yutaka Ogihara



- **Outline of Consolidated Financial Results**
 - Trends of mainstay products, Generic products

- **Consolidated Financial Forecast**

- **Status of R&D Pipeline**

- **Initiative toward realization of the long-term vision “HOPE100”**

Outline of Consolidated Financial Results


Segment Sales and Breakdown of Gain and Loss

(Units: ¥billion)	Sep/20	Sep/21	Change	Change (%)	Change (forecast) Announced on May 11,2021
Sales	47.7	49.1	n/a	n/a	+1.8
New ethical drugs, etc. (Japan)	32.9	33.3	n/a	n/a	+1.4
New ethical drugs (Overseas)	0.5	0.3	n/a	n/a	-0.2
Generic drugs	14.4	15.5	n/a	n/a	+0.7
Cost of Sales	22.9	26.7	n/a	n/a	-
SG&A (R&D)	23.3 (5.2)	22.4 (4.4)	n/a (-0.8)	-1.9 (-16.1)	- (-0.5)
Operating Income	1.5	-0.1	-1.6	-	+0.7
Ordinary Income	1.8	0.3	-1.5	-84.2	+0.9
Net Income	2.1	0.1	-2.0	-94.3	+0.4

* From the beginning of the current term, "Accounting Standards for Revenue Recognition" (ASBJ Statement No. 29, Mar.31,2020) etc. have been applied, and the revenue recognition standards for the previous second quarter is different from the current second quarter, the amount of increase / decrease compared to the second quarter and the Year on Year change rate (%) are not shown. There is no impact on operating loss, ordinary income, and net income.

Highlights of Business Performance: ① Net sales

(Units: ¥billion)



New ethical drugs, etc. (Japan)
Increased

- New drugs (Beova, Desalex, Lasvic) grew
- Sales of long-listed products (Pentasa etc.)

New ethical drugs (Overseas)
Decreased


Generic drugs
Increased

- Sales increase in 3 AG products (Kipres AG, etc.)
- New generic drugs in June contributed to sales

Highlights of Business Performance :

② Operating Income

(Units : ¥billion)



Net sales increased

Cost of sales ratio increased

<Reasons of increase>

- Impact of NHI drug price revision (Kyorin Pharmaceutical : 6% range)
- Sales of Generic drugs increased
- Loss on retirement of inventories, etc. increased

<Reason of decrease>

- Product mix

Gross profit decreased

SG&A cost decreased

- Cost of R&D cost decreased
Upfront payment for AKP-009 in FY20
- SG&A(excluding R&D) remained flat
Cost reduction
Upfront payment for Gefapixant citrate

Operating income decreased

Highlights of Business Performance:

③ Change (forecast)

(Units : ¥billion)	Sep/20	Sep/21	Change	Change(%)	Change (forecast)
					Announced on May 11,2021
Net Sales	47.7	49.1	n/a	n/a	+1.8
New ethical drugs, etc.(Japan)	32.9	33.3	n/a	n/a	+1.4
New ethical drugs (Overseas)	0.5	0.3	n/a	n/a	-0.2
Generic drugs	14.4	15.5	n/a	n/a	+0.7
Cost of Sales	22.9	26.7	n/a	n/a	-
SG&A (R&D)	23.3 (5.2)	22.4 (4.4)	n/a (-0.8)	-1.9 (16.1)	- (-0.5)
Operating Income	1.5	-0.1	-1.6	-	+0.7
Ordinary Income	1.8	0.3	-1.5	-84.2	+0.9
Net Income	2.1	0.1	-2.0	-94.3	+0.4

■ Difference from Original Forecast(May 11, 2021)

Net Sales : Though New drug groups (Flutiform etc.) did not reach the forecast, Long-listed products (Pentasa, Kipres etc.) and Generic drugs sales were strong.

Operating Income : Gross profit also exceeded forecast as sales of new ethical drugs, etc. (Japan) and Generic drugs exceeded expectations. R & D expenses were lower than initially expected, but SG&A expenses (excluding R&D) exceeded expectations. As a result, SG & A expenses as a whole remained almost as expected, operating income exceeded expectations.



Main Product Sales Update

(Units : ¥billion)

		Sep/20	Sep/21	Change	Change(%)	Change (forecast) Announced on May 11,2021
New ethical drugs,etc. (Japan)	Flutiform (Combination drug for asthma treatment)	6.4	6.3	-0.1	-1.2	-0.3
	Desalex (Antiallergic Agent)	1.8	2.6	+0.8	+42.9	-0.2
	Beova (β3 adrenergic receptor agonist overactive bladder therapeutics)	3.8	4.3	+0.5	+14.9	+0.2
	Lasvic tablets (New quinolone synthetic antibacterial agent)	0.2	0.8	+0.6	+431.3	-0.3
	Pentasa (Ulcerative colitis and Crohn's disease treatment)	6.4	7.1	+0.7	+12.0	+1.1
	Uritos (Kyorin) (Overactive bladder)	1.6	0.7	-0.9	-57.0	+0.2
	Nasonex (Spray type allergic rhinitis remedy)	0.6	0.7	+0.1	+11.6	+0.2
	Kipres (Leukotriene Receptor Antagonist)	3.5	3.6	+0.1	+1.6	+0.6
	Mucodyne (Mucoregulant)	1.4	1.6	+0.2	+10.8	+0.4
	Milton (Disinfectant)	1.1	1.0	-0.1	-5.9	-0.1
	Rubysta (Disinfectant)	1.0	1.0	0	-0.8	0
Generic drugs	Montelukast tablets "KM" (Leukotriene Receptor Antagonist)	4.5	5.1	+0.6	+13.2	+1.1
	Mometasone Nasal 50mg "KYORIN" (Spray type allergic rhinitis remedy)	0.9	1.0	+0.1	+13.7	0
	Imidafenacin tablets & OD "KYORIN" (Overactive bladder)	0.3	0.4	+0.1	+18.1	0

Trends of mainstay products and Generic drugs

■ Main Product Flutiform (Anti-asthmatic)



Copyright © 2021 IQVIA. Calculated based on MIDAS 2017-2021 (Apr-Sep) Reprinted with permission

■ ICS/LABA market : Shrink 10.6%

¥51.1bln(FY20 first half) ⇒ ¥45.7bln(FY21 first half) ※1

- NHI drug price revision
- Generic for a competitive product
- Impact from triple therapy(ICS/LABA/LAMA)

■ Share of Flutiform sales : expanded 0.6%

15.2% (FY20 first half) ⇒ 15.8%(FY21 first half) ※1

[NHI price revision 125aerosolized 120 for inhalation ▲6.3% (Compared with Apr,2020)]

■ Status in first half 2021



- Proactively developed web seminar and briefing
- Competition with triple therapy

■ Effort for FY 2021

Establish the "First Choice for Asthma Treatment Position

- Appeal the utility of the aerosol formulations
To get understanding and permeate the significance of administration to patients with cough symptoms
- Penetrate pediatric indications and increase market share
- Provide information according to "Practical guideline for Asthma management"

■ Main Product Desalex (Antiallergic Agent)



Copyright © 2020 IQVIA. Calculated based on MIDAS 2017-2021 (Apr-Sep) Reprinted with permission

■ Antihistamine market : shrink 4.7%

¥58.7bln(FY20 first half) ⇒ ¥55.9bln(FY21 first half) ※1

- Market shrinking due to NHI drug price revision and launch of Generic drugs etc.

■ Share of Desalex sales

4.1%(FY20 first half)⇒ 5.9% (FY21 first half)※1

- Dec. 18 single month : 6.3%※2(Before supply suspension)
- Sep.21 single month : 6.2%※1

[NHI price revision ▲8.3% (compared with Ap,2020)]

※1 Copyright © 2021 IQVIA. Calculated based on MIDAS 2020.4-9,2021.4-9 Reprinted with permission
 ※2 Copyright © 2021 IQVIA. Calculated based on MIDAS 2018.12, 2021.9 Reprinted with permission




■ Status in first half 2021

- Amount of pollen dispersed in spring was lower than usual
- Accelerated effort for skin disease in internal medicine and expanded adoption in medical institutions

■ Effort for FY2021

- Aim to be No. 1 prescription in otolaryngology
- Focus on acquiring prescriptions in internal medicine

■ Main Product Beova/Uritos (OAB)



Copyright © 2021 IQVIA. Calculated based on MIDAS 2017-2021(Apr-Sep) Reprinted with permission

■ Status in first half 2021

OAB market : expand 2.5%

¥48.5bln(FY20 first half)⇒¥47.3bln (FY21 first half) ※1
 ・β3 adrenergic receptor agonist market expanded

● Share of Beova sales

8.9%(FY20 first half)⇒9.2%(FY21 first half)※1

● Share of Uritos sales

4.1%(FY20 first half)⇒1.7%(FY21 first half)※1

[NIH price revision Beova▲3.8%,Uritos▲6.6% (compared with Apr.2020)]



■ Effort for FY2021

- Aim to contribute to urology together with Zymso *1
- After clearing shipping adjustment ※, aim for the top share soon

※: At each OEM manufacturer, they are working to expand facilities and launch new manufacturing sites. Shipment adjustments are expected to be lifted during FY2022

※1 Copyright © 2021 IQVIA. Calculated based on MIDAS 2020.4-9,2021.4-9 Reprinted with permission

■ Main Product Lasvic (New quinolone synthetic antibacterial agent)



Copyright © 2021 IQVIA. Calculated based on MIDAS 2017-2021(Apr-Sep) Reprinted with permission

■ Oral antimicrobial market : expand 1.7%

¥30.7bln (FY 20 first half) ⇒ ¥31.3bln (FY 21 first half)^{※1}

- Prevent infection (washing hands, gargling, wearing masks, etc.) has continued to reduce the number of infectious diseases, and the market remained flat

■ Share of Lasvic sales

1.4% (FY 20 first half) ⇒ 2.7%(FY 21 first half)^{※1}

[NHI price revision ▲2.2% (compared with Apr.2020)]

※1 Copyright © 2020 IQVIA. Calculated based on MIDAS 2020.4-9,2021.4-9 Reprinted with permission



■ Status in first half 2021

- Actively provide solution (Prevention, Diagnosis, Medication) in the infection field
- Continue cognitive activities for diseases and AMR through web seminar

■ Effort for FY2021

- Appeal that both dosage forms can cover respiratory infections
- Increase in-hospital and outpatient treatment options
 Tablets: Aim to maximize product penetration
 Injection: Aim for early adoption and widespread use

■ Status of Generic Drugs



■ Status in first half 2021

Action for an authorized generic drug(AG)

- Montelukast AG, Mometasone AG, Imidafenacin AG maintain the market share of more than 50% in the GE market

GE drugs released in Jun 21 (3 ingredients 5 items)

Eszopiclone 1mg/2mg/3mg, Epinastine hydrochloride ophthalmic Solution 0.05%, Tadalafil 20mg OD

■ Effort for FY2021

Promotion of AG strategy

- Aim to achieve a market share of more than 50% for each AG product in GE market

GE drugs to be released in Dec 21(2 ingredients 4 items)

Levetiracetam 250mg/500mg/DS50%, Olopatadine Ophthalmic Solution 0.1%

Consolidated Financial Forecast

Consolidated Financial Forecast in FY2021

(Units : ¥billion)	FY2020	FY2021 (forecast)	Y/Y	
			Change	Change(%)
Net sales	102.9	102.6	n/a	n/a
New ethical drugs, etc.(Japan)	69.7	68.6	n/a	n/a
New ethical drugs (Overseas)	1.0	0.8	n/a	n/a
Generic drugs	32.2	33.1	n/a	n/a
Cost of Sales	51.3	—	—	—
SG&A (R&D)	45.8 (9.7)	— (9.2)	— (-0.5)	— (-5.2)
Operating Income	5.8	3.3	-2.5	-43.0
Ordinary Income	6.4	3.8	-2.6	-41.1
Net Income	6.1	2.7	-3.4	-56.0

※The results forecasts for the full year announced on May 11, 2021 remain unchanged

Net Sales: Although sales of main products (Desalex, Lasvic, etc.) will grow, sales of new ethical drugs (Japan) are expected to decrease due to NHI drug price revisions (Kyorin Pharmaceutical 6% range). Meanwhile, GE's sales are expected to increase

Operating Income: Gross profit decrease due to a decrease in sales. Despite efforts to reduce SG & A expenses (including R&D expenses), profits are expected to decline due to investment costs to expand the development pipeline

Cost of sales ratio: Increase about 3.5 points, SG&A expenses ratio (excluding R&D expenses): Decrease about 1 point, R&D: Decrease ¥0.5 bln (¥9.7 bln ⇒¥9.2 bln)

* From the beginning of the current term, "Accounting Standards for Revenue Recognition" (ASBJ Statement No. 29, Mar.31,2020) etc. have been applied, and the revenue recognition standards for the previous second quarter is different from the current second quarter, the amount of increase / decrease compared to the second quarter and the Year on Year change rate (%) are not shown. There is no impact on operating loss, ordinary income, and net income.

Forecast of Mainstay Products Sales

(Units : ¥billion)		FY2020 (Actual)	FY2021 (Forecast)	YoY	
				Change	Change(%)
New ethical drugs,etc. (Japan)	Flutiform (Combination drug for asthma treatment)	13.3	13.9	+0.6	+4.8
	Desalex (Antiallergic Agent)	5.7	7.2	+1.5	+27.2
	Beova(Kyorin) (β3 adrenergic receptor agonist overactive bladder therapeutics)	7.3	8.6	+1.3	+18.3
	Lasvic (New quinolone synthetic antibacterial agent)	0.9	2.8	+1.9	+229.0
	Pentasa (Ulcerative colitis and Crohn's disease treatment)	12.8	11.7	-1.1	-7.8
	Uritos (Kyorin) (Overactive bladder)	2.3	1.0	-1.3	-56.3
	Nasonex (Spray type allergic rhinitis remedy)	2.8	1.8	-1.0	-33.7
	Kipres (Leukotriene Receptor Antagonist)	8.3	6.9	-1.4	-16.1
	Mucodyne (Mucoregulant)	3.3	2.9	-0.4	-9.6
	Milton (Disinfectant)	2.1	2.2	+0.1	+5.6
	Rubysta (Disinfectant)	2.0	2.1	+0.1	+8.3
Generic drugs	Montelukast tablets "KM" (Leukotriene Receptor Antagonist)	10.8	9.2	-1.6	-14.2
	Mometasone Nasal 50mg "KYORIN" (Spray type allergic rhinitis remedy)	3.8	3.5	-0.3	-6.4
	Imidafenacin tablets & OD "KYORIN" (Overactive bladder)	0.7	0.7	0	+5.9

※The results forecasts for the full year announced on May 11, 2021 remain unchanged

Shareholder Returns

Capital Policy

- While maintaining the sound financial base, we aim to improve the capital efficiency through growth investment and returns to shareholders
- We will maintain stable dividends taking DOE (Dividend on Equity ratio) into account

Revision of Dividend Level

In consideration of dramatic changes in the business environment, rising demand for growth investments such as expansion of development pipelines, investment in facilities, we lowered the level of DOE while maintaining the capital policy

Dividend

	FY2019	FY2020	FY2021 (Plan)
Dividend per Share	¥75 (Interim ¥30)	¥75 (Interim ¥30)	¥52 (Interim ¥20)

※ There is no change in the dividend plan (¥52/year) announced on May 11, 2021.

◆ The interim dividend of ¥20 was resolved by the Board of Directors on November 8, 2021 17

Application for New Market Segment “Prime Market” on the Tokyo Stock Exchange

KYORIN Holdings, Inc. (Head Office: Chiyoda-ku Tokyo Japan, hereafter “KYORIN”) received on July 9, 2021 the results of the initial assessment of its compliance with the listing standards of the new market segments to be introduced on April 4, 2022 from the Tokyo Stock Exchange (hereafter the “TSE”), and confirmed its compliance with the listing standards for the “Prime Market”.

Based on these results, at the Board of Directors Meeting held on November 8, 2021, KYORIN resolved to select the new market segment “Prime Market” as its listing market (Press release on November 8, 2021)






Hence, KYORIN will follow the prescribed procedures related to the application for the selection of the new market segment, in accordance with the schedule set by the TSE.

Status of R&D Pipeline

Drug R&D Pipeline: Progress



Plan in FY2020

	development code	Ph I	Ph II	Ph III	application	Approval/ Launch
Respiratory	KRP-R120					
	Gefapixant citrate					
Infections	KRP-A218					
Urology	KRP-116D					
	AKP-009					

※ Gefapixant citrate: Concluded Distribution Agreement in Japan with MSD (Apr 2021)

【 Licensed Compound / Program 】

Compound/Code	Licensee	Stage	Features
FPR2 agonist program	BMS	Ph I	<ul style="list-style-type: none"> • FPR-2 agonists that mainly inhibit the migration of neutrophils and exhibit anti-inflammatory action. • Therapy area : Non-disclosure
KRP-203	Priothera	Ph I	<ul style="list-style-type: none"> • Sphingosine-1-Phosphate Receptor Agonist • Target: AML patients undergoing HSCT • Assignment of intellectual properties and drug substances(Sep.2020)
Compound for Sensorineural Hearing Loss	Otonomy	Non-clinical	<ul style="list-style-type: none"> • 「OTO-6XX」 (Otonomy's Development Code) • License Agreement (Aug.2020)

Drug R&D Pipeline: Progress



Progress in FY2021

	development code	Ph I	Ph II	Ph III	application	Approval/ Launch
Respiratory	KRP-R120	Completed				
	Gefapixant citrate				MSD (Feb)	
Infections	KRP-A218	(Apr)				
Urology	KRP-116D					Launched (Apr)
	AKP-009		ASKA interrupted			

※ASKA started an additional Ph I study to confirm the maximum effect at a higher dose

【 Licensed Compound / Program 】

Compound/Code	Licensee	Stage	Features
FPR2 agonist program	BMS	Ph I	<ul style="list-style-type: none"> •FPR-2 agonists that mainly inhibit the migration of neutrophils and exhibit anti-inflammatory action. •Therapy area : Non-disclosure
KRP-203	Priothera	Ph I	<ul style="list-style-type: none"> •Sphingosine-1-Phosphate Receptor Agonist • Target : AML patients undergoing HSCT •Assignment of intellectual properties and drug substances(Sep.2020)
Compound for Sensorineural Hearing Loss	Otonomy	Non-clinical	<ul style="list-style-type: none"> •「OTO-6XX」 (Otonomy's Development Code) •License Agreement (Aug.2020)

**Initiative toward realization of
the long-term vision “HOPE 100”**

Overview of Medium-Term Business Plan *Kyorin*

“HOPE 100-Stage 3-”

Statement : Realize growth trend by pursuing Kyorin’s originality

Business Strategy

- Shift to business based on the proposal of solutions and accelerate the growth of new drug groups.
- Enhance pipeline to support medium-term growth
- Strengthen drug discovery capability to realize the creation of innovative new drugs.
- Improve cost competitiveness
- Expand overseas revenue

Organization Strategy

- Aim to be the No. 1 company for career fulfillment

Performance Targets

- Growth potential and profitability
- Capital policy and shareholder returns


Response to changing environment
(MR activities/Medical care provision system)

Rebuild sales structure and enhance details

"Lasvic tablets 75mg "
"Lasvic IV Drip Infusion Kit 150mg"
• Contribute to respiratory and ENT infection along with tablets
"KRP-A218"(Rhinovirus)Ph I
• Expand pipeline in infection medicines

Shift to business based on proposal of solutions

Contribution to infection control in medical institutions



GeneSoC®
PCR pretreatment kit launched (Jul)
Aim to launch IVD
GeneSoC mini will be launched (Notified as a medical device in Oct)

* ICT: Infection Control Team
AST: Antimicrobial Stewardship Team



Infection-related product sales ¥5.8 bln(FY20) ⇒ ¥8.3 bln(FY21:forecast)

Kyorin's unique contribution to health care workers in the infection fields

Effort in diagnosis business

“Genetic Analyzer GeneSoC[®] mini

Launch: End of Nov

	GeneSoC[®] mini	GeneSoC[®]
Aspect	 Diameter 10.5cm/Height 15.5cm	 Width 62cm/Depth 29cm//Height 15.4cm
Notification	General medical device	Laboratory equipment
Principle	RT-PCR	RT-PCR
Specimen/Test	1	1~4
Detecting time	5~15 min	5~15 min
Price (with Tax)	¥1,152,800	¥3,278,000 (Body+1 Unit)
Weight	0.65kg (Body)	4kg (Body) + 1kg (Unit)

Characteristics of GeneSoC[®] mini : Lightweight·Compact/Rapid/Low price

Promote the use as a POCT * compatible device and develop reagents as IVD (in-vitro diagnostic drug) aiming to contribute to the proper use of antimicrobial drugs

Interstitial cystitis “Zymso Intravesical Solution 50%”

Launched : Apr 2021

▶ As a new treatment, Zymso contributes to patient treatment and better QOL

Indication : Improvement of symptoms of interstitial cystitis (Hunner type) (chronic pelvic pain, pressure and discomfort associated with the bladder, lower urinary tract symptoms such as increased urgency or pollakiuria)



- Characteristics:**
- First therapeutic agent for interstitial cystitis
 - Exhibits anti-inflammatory effect, shows sedative and analgesic effects on inflammation in the bladder

“Gefapixant Citrate” a Treatment for Chronic Cough

▶ MSD’s drug application (Feb), KYORIN’s Exclusive distribution rights (Apr)

Target treatment: Refractory chronic cough (RCC) or unexplained chronic cough (UCC)
(Reported that the prevalence of chronic cough in Japan is about 2% among Japanese 16 years and older) Fujimura, Allergology International. 2012; 61: 573-581

Characteristics: Currently, there is no therapeutic drug with the indication or effect of RCC and UCC, and Gefapixant is expected as a new treatment option

Pulmonary sarcoidosis treatment "KRP-R120"



aTyr社 ATYR1923 Ph 1b/2a Study

Trial Design

Design	<ul style="list-style-type: none"> • Randomized (2:1), double-blind, placebo-controlled, multiple ascending dose • 24 week study: 6monthly IV dose of ATYR1923 being tested at 1.0, 3.0, 5.0 mg/kg • Forced steroid taper to 5.0 mg by week 8; amendment to allow taper to 0 mg at week 16 in responders
Population	<ul style="list-style-type: none"> • 37 histologically confirmed pulmonary sarcoidosis patients
Endpoints	<p>[Primary Endpoint]</p> <ul style="list-style-type: none"> • Safety and tolerability of multiple ascending IV ATYR1923 doses <p>[Secondary Endpoint]</p> <ul style="list-style-type: none"> • Steroid-sparing effect • Immunogenicity • Pharmacokinetics(PK) • Exploratory : Lung function (FVC and other PFTs); sarcoidosis symptom scores and quality of life scales; inflammatory and sarcoidosis biomarkers; FDG-PET/CT imaging

Reference : ATYR Pharma Conference Call and Webcast(Sep 13, 2021)

Pulmonary sarcoidosis treatment "KRP-R120"



Primary Endpoint

- The trial met its endpoint : Safe and well-tolerated

Secondary Endpoint

- 58% overall steroid reduction from baseline and 22% relative reduction in steroid utilization post taper in the 5.0mg/kg treatment group
- 33% of patients able to taper completely off steroids in the 5.0mg/kg treatment group
- 3.3% absolute improvement in lung function as measured by FVC% predicted at week 24 in the 5.0mg/kg treatment group
- Dose-dependent clinically meaningful improvement in all sarcoidosis symptom measures in the 5.0mg/kg treatment group
- Dose-dependent improvement on inflammatory biomarkers including IL-6, MCP-1, IFN- γ , IP-10 and TNF α as well as sarcoidosis markers ACE, IL-2Ra and SAA with tightest control in the 5.0mg/kg treatment group

Reference : ATYR Pharma Conference Call and Webcast(Sep 13, 2021)

Kyorin is initiating investigation to proceed to the next stage of development such as MRCT together with aTyr

Treatment agent for BPH “AKP-009”

Development Outline

- **Ph II a study** (Randomized, double-blind, parallel-group comparative study with placebo as a control)
- **Target treatment** : Benign Prostatic Hyperplasia patients
- **Number** : About 100
- **Frequency of administration** : Once a day
- **Primary endpoint** : Safety & efficacy(Rate of change from baseline in prostate volume at 12 weeks of administration)


Development Result

No statistically significant dose correlation was found, and no significant difference was found for each active group compared to the placebo group

Next Step

Based on the results of the Ph II a study, it is necessary to conduct clinical study at a higher dose in order to confirm the maximum effect, and Aska Pharmaceutical started an additional Ph I study in September.

Strengthen drug discovery capability to realize the creation of innovative new drugs



“KPR-A218” a Treatment for Rhinovirus infection

Development background

Discovered from Kinase research by Watarase Drug Discovery Center and ActivX in the United States

Development status

Started Ph I in Apr 2021 in England

Target Treatment

Rhinovirus infection at risk of aggravation

Rhinovirus is known as the causative virus of the common cold, but the risk of developing a lower respiratory tract infection is becoming recognized as a medical issue in immunocompromised patients.

Mode of Action

An antiviral drug that targets host molecules and suppresses viral growth in the body

- Expected to be widely effective against many rhinovirus serotypes (types of surface antigens)
- Less generate resistant virus by mutant strain

“Discovery for Lung Diseases” course at Graduate School of Kyoto University (Phase 2)

Purpose of Joint Research

A joint research course "Discovery for Lung Disease" was established in 2017 at the Graduate School of Medicine, Kyoto University. The joint research was extended for three years in 2020, aiming to create innovative therapeutic drugs originating in Japan, by integrating the pathological research and basic research capabilities of the Kyoto University Graduate School with the drug discovery capabilities of Kyorin Pharmaceutical, and identifying various factors that are deeply involved in the pathophysiology of respiratory disease, and proceed with the search for new targets through validation research on the potential as drug discovery targets


- ▶ Research on the pathophysiology of organ fibrosis processes such as pulmonary fibrosis based on both technologies (continued from phase 1)
- ▶ Promote patient stratification research with a view to clinical application in collaboration with the Department of Respiratory Medicine, Kyoto University, for candidate compounds for new drug discovery targets (Phase 2)

Outline of Joint Research

Place :	Graduate school of Medicine, Kyoto University
Name:	Discovery for Lung Disease Course
Faculty:	Associate Professor Shimpei Gotoh (Ex assistant professor, iPS group leader, Department of Respiratory Medicine, Graduate School of Kyoto University) Assistant Professor Masayasu Toyomoto (Ex assistant professor, Department of Anatomy and Developmental biology, Graduate School of Kyoto University)
Terms :	April 1, 2021 – March 31, 2023
Contributions :	About ¥200 Million / 3 years

Accelerate growth of new drug groups

- Maximize the spread of Flutiform and Desalex
- Establish Lasvic's position as a quinolone for respiratory and otolaryngological infections
- Accelerate growth of Beova (FY2022)
- Preparation for Gefapixant citrate



This material contains performance forecasts, goals and plans, and other forward-looking statements related to the Group.

These statements are based on the judgment of the Group's assumptions and outlooks based on the information and forecasts available at the time of preparation of this material, and contain known or unknown risks and uncertainties. Therefore, due to various factors that may occur, the actual performance, progress / success / failure of the development and other insights may differ significantly from the description. It also contains information about medicines (including those under development), but the description is not for the purpose of advertising or medical advice.

Kyorin 